Research programme: anticancer antibody - Arana Therapeutics

Drug Profile

Research programme: anticancer antibody - Arana Therapeutics

Alternative Names: ART-101; SC 101

Latest Information Update: 21 Aug 2009

Price : $50

At a glance

  • Originator Scancell
  • Class Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Lewis Y antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Colorectal cancer

Most Recent Events

  • 10 Aug 2009 Arana Therapeutics has become a wholly-owned subsidiary of Cephalon
  • 16 Mar 2009 Early research in Colorectal cancer in Australia (Parenteral)
  • 09 May 2007 Peptech Ltd. has received a $A6.6 million grant from the Australian Government's Pharmaceuticals Partnerships Program
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top